Literature DB >> 2522095

Effect of photofrin II and light energy on retinoblastoma-like cells in vitro. Dose-response relationships, effect of light dose rate and recovery ratio.

J Winther1.   

Abstract

A clonogenic survival assay on retinoblastoma-like cells (EXP-5 cells) was applied in vitro to assess the effect of photodynamic therapy at relative low concentrations of photofrin II and high doses of light energy. The cellular concentration of photofrin II was estimated by spectrofluorimetry. The cellular content of photofrin II increased with the concentration in the medium (up to 3 micrograms/ml) and the incubation time (up to 24 h) in cells first incubated in photofrin II for 24 h and then in photofrin-II-free medium for 24 h. There was an obvious dose-response relationship between cell damage and photodynamic therapy both for the cellular photofrin II content and the total amount of light energy delivered. The dose rate of light energy had no influence on the cell damage. The cells had a recovery factor of only 1.34, suggesting a low repair of sublethal damage. An approximately linear isoeffect curve at the 10% survival level was described as a function of photofrin II concentration and light energy, suggesting a predictable reversible relationship between them. The results suggest that retinoblastoma cells are very sensitive to photodynamic therapy.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2522095     DOI: 10.1007/bf00391603

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  22 in total

Review 1.  Photosensitizers: therapy and detection of malignant tumors.

Authors:  T J Dougherty
Journal:  Photochem Photobiol       Date:  1987-06       Impact factor: 3.421

Review 2.  Porphyrin photosensitization and phototherapy.

Authors:  J Moan
Journal:  Photochem Photobiol       Date:  1986-06       Impact factor: 3.421

3.  The effect of photodynamic therapy alone and in combination with misonidazole or X-rays for management of a retinoblastoma-like tumour.

Authors:  J Winther; J Overgaard; N Ehlers
Journal:  Photochem Photobiol       Date:  1988-03       Impact factor: 3.421

4.  Photodynamic inactivation of R3230AC mammary carcinoma in vitro with hematoporphyrin derivative: effects of dose, time, and serum on uptake and phototoxicity.

Authors:  R Hilf; P B Leakey; S J Sollott; S L Gibson
Journal:  Photochem Photobiol       Date:  1983-06       Impact factor: 3.421

5.  Membrane lysis in Chinese hamster ovary cells treated with hemtoporphyrin derivative plus light.

Authors:  D A Bellnier; T J Dougherty
Journal:  Photochem Photobiol       Date:  1982-07       Impact factor: 3.421

6.  Expression of potentially lethal damage in Chinese hamster cells exposed to hematoporphyrin derivative photodynamic therapy.

Authors:  C J Gomer; N Rucker; A Ferrario; A L Murphree
Journal:  Cancer Res       Date:  1986-07       Impact factor: 12.701

7.  Hematoporphyrin phototherapy of cancer.

Authors:  M W Berns; A G Wile
Journal:  Radiother Oncol       Date:  1986-11       Impact factor: 6.280

8.  Characterization of an intraocular retinoblastoma-like tumour.

Authors:  J Winther; O A Jensen; J U Prause; N Tommerup
Journal:  Acta Ophthalmol (Copenh)       Date:  1987-08

9.  Photosensitization and split-dose recovery in cultured human urinary bladder carcinoma cells containing nonexchangeable hematoporphyrin derivative.

Authors:  D A Bellnier; C W Lin
Journal:  Cancer Res       Date:  1985-06       Impact factor: 12.701

10.  Tumor destruction and kinetics of tumor cell death in two experimental mouse tumors following photodynamic therapy.

Authors:  B W Henderson; S M Waldow; T S Mang; W R Potter; P B Malone; T J Dougherty
Journal:  Cancer Res       Date:  1985-02       Impact factor: 12.701

View more
  1 in total

1.  Photodynamic therapy effect in an intraocular retinoblastoma-like tumour assessed by an in vivo to in vitro colony forming assay.

Authors:  J Winther
Journal:  Br J Cancer       Date:  1989-06       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.